SanBio Company Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNBIF research report →
About the company
SanBio Company Limited is a biopharmaceutical firm specializing in the development, manufacture, and commercialization of regenerative cell therapies, with a primary focus on disorders of the central nervous system. A significant product in its portfolio is SB623, which has successfully completed Phase 2 clinical trials in both the United States and Japan for the treatment of traumatic brain injury (TBI). The company's research pipeline also explores the potential of SB623 for a variety of other conditions, including ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease, among others.
- CEO
- Keita Mori
- IPO
- 2015
- Employees
- 29
- HQ
- Tokyo, JP
Price Chart
- Market Cap
- $1.28B
- P/E
- -25.58
- P/S
- 0.00
- P/B
- 6.60
- EV/EBITDA
- -20.79
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -44.85%
- ROIC
- -24.78%
- Revenue
- $0 · 0.00%
- Net Income
- $-3,842,146,194 · -33.32%
- EPS
- $-52.63 · -25.76%
- Op Income
- $-3,794,349,976
- FCF YoY
- -6.37%
- 52W High
- $16.45
- 52W Low
- $3.85
- 50D MA
- $16.45
- 200D MA
- $16.45
- Beta
- 0.28
- Avg Volume
- 581.748
Get TickerSpark's AI analysis on SNBIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SNBIF coverage
Recent articles, reports, and earnings notes.
No research on SNBIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SNBIF report →Similar companies
Peers in the same neighborhood.